This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices
by Zacks Equity Research
For those who thought that the pharma/biotech sector is in for an extraordinary run after Donald Trump's unexpected victory, his latest vow to crack down on excessive drug price hikes comes as a bolt from the blue.
Lilly: Jardiance Label to Add Cardiovascular Indication
by Zacks Equity Research
Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on its type II diabetes drug Jardiance's (SGLT-2 inhibitor) label.
J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
by Zacks Equity Research
Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.
Stock Market News for November 25, 2016
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen
Under Armour Beats Q3 Earnings, Stock Down 14%
by Mark Vickery
Profit margins are down year over year, and Under Armour on its conference call illustrated the need to spend on advertising to keep up in its very competitive market.
Analyst Reports for Netflix, Halliburton & Disney
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Halliburton (HAL), Netflix (NFLX) and Disney (DIS).
Top Stocks with Big Potential Catch-Up Moves
by Kevin Matras
Given the recent run-up in the market, here's a screen I've been using recently. Highlighted stocks include AMSF, CTSH, DOOR, KFY and LLY.
4 Health Care Stocks to Watch Out for this Earnings Season
by Zacks Equity Research
Health care companies have been attracting a lot of attention lately.